Cogent Biosciences, Inc. (COGT)
NASDAQ: COGT · Real-Time Price · USD
5.98
-0.50 (-7.72%)
Mar 31, 2025, 1:23 PM EDT - Market open
Cogent Biosciences Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Cogent Biosciences stock have an average target of 14.17, with a low estimate of 8.00 and a high estimate of 21. The average target predicts an increase of 136.96% from the current stock price of 5.98.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Cogent Biosciences stock from 7 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 2 |
| Hold | 2 | 2 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Scotiabank | Scotiabank | Buy Initiates $17 | Buy | Initiates | $17 | +184.28% | Mar 7, 2025 |
| Baird | Baird | Hold Maintains $10 → $8 | Hold | Maintains | $10 → $8 | +33.78% | Feb 27, 2025 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Feb 26, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $17 → $14 | Strong Buy | Maintains | $17 → $14 | +134.11% | Jan 14, 2025 |
| Needham | Needham | Strong Buy → Hold Downgrades $15 | Strong Buy → Hold | Downgrades | $15 | +150.84% | Dec 11, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
46.23M
EPS This Year
-2.18
from -2.46
EPS Next Year
-1.79
from -2.18
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 119.5M | 640.9M | ||
| Avg | n/a | 46.2M | 235.1M | ||
| Low | n/a | 2.7M | 71.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 1,286.4% | ||
| Avg | - | - | 408.5% | ||
| Low | - | - | 53.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.72 | -1.48 | 1.18 | ||
| Avg | -2.18 | -1.79 | -0.76 | ||
| Low | -2.60 | -2.53 | -1.43 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.